Alzheimer's Drug Given Full FDA Approval

In a positive step forward for Alzheimer's disease treatment, the Food and Drug Administration (FDA) last Thursday evening granted full approval for a new drug called Leqembi. Leqembi is the first drug of its kind with clear evidence it can slow cognitive decline in people with early stages of the disease. The full approval means Medicare can start covering the cost of treatment for patients, making it more widely available. "This gives people more months of recognizing their spouse, children and grandchildren," said Joanne Pike, CEO and president of the Alzheimer's Association. Read more from ABC News here.